Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191035 · ClinicalTrials.gov registry record · Phase 4
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 520
- Enrollment target
NCT00191035: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00191035 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 520 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00191035, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 520 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
What the finished NCT00191035 record still lists
NCT00191035 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00191035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00191035 about?
NCT00191035 is a clinical study titled "Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD". The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
What is the current status of trial NCT00191035?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 520 participants. The study started on 2004-03. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00191035?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00191035?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00191035's enrollment target sits among peer trials
520 159th of 2000 higher than 1,842 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia